The Trust Gap: Why Doctors And Patients Still Hesitate To Adopt Biosimilars In India?

Biosimilars gave a surety to advance access to biological therapies, particularly in countries with low resources such as India. These alternatives show reliability as a cost-effective solution that matches the innocuousness and utility of existing treatments yet remains underused in the medical environment. The main reason for this situation is that a mutual distrust persists among healthcare workers and patients. Doctors prescribe medications differently and patients respond towards treatments because of their concerns regarding immunogenicity, lack of information about biologically similar drugs and limited knowledge of the governing system’s function. India is a market for biosimilars, due to its strong manufacturing capabilities and expanding biosimilar portfolio. However, optimal utilization remains a challenge. Clinical studies and real-world evidence show that biosimilars are trustworthy through studies on trastuzumab and other medications. Educational programs, clear regulatory information and better communication methods can address perception-based barriers because they will increase biosimilar acceptance in standard healthcare procedures.